Asia Pacific Human Vaccine Adjuvants Market Forecast to 2030
Asia Pacific Human Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Growing Pharmaceutical Industry Boosts Asia Pacific Human Vaccine Adjuvants Market
The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry’s increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases. According to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world’s largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world’s generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare’s (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion. As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the Asia Pacific human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the Asia Pacific human vaccine adjuvants market in the coming years.
Asia Pacific Human Vaccine Adjuvants Market Overview
China has invested heavily in its healthcare and pharmaceutical industries, aiming to bolster domestic production, research, and development capabilities. This strategic focus has positioned the country as a key player in the Asia Pacific human vaccine adjuvants market. Additionally, China is among the most densely populated countries in the world; the current population is ~1.41 billion. According to the latest Global Burden of Disease (GBD) study published in October 2020, the population in the country is prone to various infectious, chronic, and acute diseases.
An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. According to a report by the ICO/IARC Information Centre on HPV and Cancer in 2023, China has a population of 582.4 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. About 3.8% of women in China in the general population are estimated to harbor cervical HPV-16/18 infection at a given time, and 69.1% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the rising number of patients and the increasing demand for vaccines for treatment are also expected to boost the Asia Pacific human vaccine adjuvants market growth.
Asia Pacific Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Human Vaccine Adjuvants Market Segmentation
The Asia Pacific human vaccine adjuvants market is categorized into type, application, end user, and country.
Based on type, the Asia Pacific human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
In terms of application, the Asia Pacific human vaccine adjuvants market is categorized into influenza, hepatitis, Human Papilloma Virus (HPV), and others. The influenza segment held the largest market share in 2022.
By end user, the Asia Pacific human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
By country, the Asia Pacific human vaccine adjuvants market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific human vaccine adjuvants market share in 2022.
Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific human vaccine adjuvants market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Asia Pacific human vaccine adjuvants market was valued at US$ 330.19 million in 2022 and is expected to reach US$ 1,008.52 million by 2030, registering a CAGR of 15.0% from 2022 to 2030. Growing focus on immunization programs and growing pharmaceutical industry are among the critical factors attributed to drive the Asia Pacific human vaccine adjuvants market growth.
Governments of various nations recognize the importance of vaccination as a cost-effective strategy to prevent and control chronic diseases. According to the WHO, immunization currently prevents 3.5-5 million deaths yearly from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. As a result, governments in various nations are implementing immunization programs to reduce the incidence of diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. These programs often target specific populations, such as children, older people, and high-risk individuals, to ensure they are adequately protected against these chronic conditions. The US, India, and Australia are among the key prominent nations that have effective immunization programs. For example, India has the Universal Immunization Programme (UIP), which targets immunization of 26.7 million newborns and 29 million pregnant women annually. The United Nations International Children’s Emergency Fund (UNICEF) also offers an immunization program that provides vaccines to protect children from life-threatening diseases globally. Similarly, in collaboration with member nations, Gavi (a vaccine alliance), UNICEF, and other global immunization partners, WHO launched “The Big Catch-up” in 2023, a global vaccination drive to support efforts to catch up, restore, and improve routine immunization globally. These campaigns aim to increase vaccination coverage rates and reduce the spread of infectious diseases that can exacerbate chronic conditions. As a result, there is a growing demand for vaccines and adjuvants that can enhance the immune response and provide long-lasting protection against these diseases. Thus, all these factors boost the growth of the Asia Pacific human vaccine adjuvants market.
On the contrary, manufacturing complexities and regulatory challenges hampers the growth of Asia Pacific human vaccine adjuvants market.
Based on type, the Asia Pacific human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held 39.2% market share in 2022, amassing US$ 129.58 million. It is projected to garner US$ 390.28 million by 2030 to register 14.8% CAGR during 2022-2030.
In terms of application, the Asia Pacific human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held 37.6% share of Asia Pacific human vaccine adjuvants market in 2022, amassing US$ 124.30 million. It is anticipated to garner US$ 393.00 million by 2030 to expand at 15.5% CAGR during 2022-2030.
By end user, the Asia Pacific human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held 48.8% share of Asia Pacific human vaccine adjuvants market in 2022, amassing US$ 161.17 million. It is projected to garner US$ 509.37 million by 2030 to expand at 15.5% CAGR from 2022 to 2030.
By country, the Asia Pacific human vaccine adjuvants market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.0% share of Asia Pacific human vaccine adjuvants market in 2022. It was assessed at US$ 89.14 million in 2022 and is likely to hit US$ 281.73 million by 2030, registering a CAGR of 15.5% during 2022-2030.
Key players operating in the Asia Pacific human vaccine adjuvants market are Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific human vaccine adjuvants market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The the Reporting Teams Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Human Vaccine Adjuvants Market – Key Market Dynamics
4.1 Asia Pacific Human Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market – Asia Pacific Market Analysis
5.1 Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 – 2030
5.2 Asia Pacific Human Vaccine Adjuvants Market Forecast Analysis
6. Asia Pacific Human Vaccine Adjuvants Market Analysis – by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Human Vaccine Adjuvants Market Analysis – by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
7.3.1 Overview
7.3.2 Human papilloma virus (HPV): Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Human Vaccine Adjuvants Market Analysis – by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Human Vaccine Adjuvants Market – Country Analysis
9.1 Asia Pacific
9.1.1 Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 China Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 China Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 China Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 China Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 Japan Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Japan Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 Japan Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 Japan Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 India Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 India Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 India Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 India Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.4 Australia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Australia Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.4.2 Australia Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.4.3 Australia Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.5 South Korea Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.5.1 South Korea Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.5.2 South Korea Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.5.3 South Korea Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.6 Rest of Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.6.1 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.6.2 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.6.3 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Dynavax Technologies Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 CSL Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Seppic SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 SPI Pharma Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hawaii Biotech Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Croda International Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Novavax Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Phibro Animal Health Corp
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The the Reporting Teams
12.2 Glossary of Terms
Table 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation
Table 2. Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 4. Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Application
Table 5. Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 6. China Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. China Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 8. China Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 9. Japan Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 10. Japan Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 11. Japan Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 12. India Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. India Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 14. India Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 15. Australia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 16. Australia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 17. Australia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 18. South Korea Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 19. South Korea Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 20. South Korea Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 21. Rest of Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 22. Rest of Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 23. Rest of Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market
Figure 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
Figure 4. Asia Pacific Human Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Human Vaccine Adjuvants Market Share (%) – by Application (2022 and 2030)
Figure 10. Influenza: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human Papilloma Virus (HPV): Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Human Vaccine Adjuvants Market Share (%) – by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries – Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. China Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 21. Japan Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 22. India Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 23. Australia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 24. South Korea Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Asia Pacific Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
The List of Companies – Asia Pacific Human Vaccine Adjuvants Market
1. Croda International Plc
2. CSL Ltd
3. Dynavax Technologies Corp
4. Hawaii Biotech Inc
5. Novartis AG
6. Novavax Inc
7. Phibro Animal Health Corp
8. Seppic SA
9. SPI Pharma Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.